Published in Immunotherapy Weekly, August 31st, 2005
CureLab has developed patent-pending, proprietary technology that it believes will enable it to develop a vaccine that would be effective against all strains of the flu virus, both known and unknown. This award from the NIH is the first phase of a 2-phase grant under the small business innovation research biodefense program. CureLab expects that the total amount of this award will be $7 million.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.